Login to Your Account



AVEO Files $86M IPO to Support New Phase III Kidney Cancer Trial

By Trista Morrison


Friday, December 18, 2009
AVEO Pharmaceuticals Inc. was on the short-list of biotechs rumored to be planning an initial public offering in the current window, and the rumors proved true. The Cambridge, Mass.-based firm filed to raise $86.25 million, becoming the seventh biotech to join the IPO queue. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription